3rd Circ. Mulls Impact Of Wellbutrin Pay-For-Delay Deal
The Third Circuit grappled Wednesday with whether a GlaxoSmithKline PLC settlement aimed at keeping generic drugmakers from selling their versions of the antidepressant Wellbutrin XL fell under the U.S. Supreme Court's...To view the full article, register now.
Already a subscriber? Click here to view full article